BR112017003888A2 - método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico. - Google Patents

método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico.

Info

Publication number
BR112017003888A2
BR112017003888A2 BR112017003888-9A BR112017003888A BR112017003888A2 BR 112017003888 A2 BR112017003888 A2 BR 112017003888A2 BR 112017003888 A BR112017003888 A BR 112017003888A BR 112017003888 A2 BR112017003888 A2 BR 112017003888A2
Authority
BR
Brazil
Prior art keywords
dry powder
formulation
jet
etched
manufacturing
Prior art date
Application number
BR112017003888-9A
Other languages
English (en)
Other versions
BR112017003888B1 (pt
Inventor
Manford Fergus
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017003888(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Limited filed Critical Vectura Limited
Publication of BR112017003888A2 publication Critical patent/BR112017003888A2/pt
Publication of BR112017003888B1 publication Critical patent/BR112017003888B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

é descrito um método para a fabricação de uma composição farmacêutica para a administração pulmonar compreendendo uma comoagem por jatos de glicopirrolato e estearato de magnésio, em que os glicopirrolato e estearato de magnésio comoídos por jatos são, então, submetidos a uma etapa de condicionamento que inclui a exposição dos glicopirrolato e estearato de magnésio comoídos por jatos à umidade. também é descrita uma composição fabricada por este método.
BR112017003888-9A 2014-09-09 2015-09-09 Método de fabricação de uma formulação de pó seco BR112017003888B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09
EP14184164.3 2014-09-09
PCT/EP2015/070660 WO2016038116A1 (en) 2014-09-09 2015-09-09 Formulation comprising glycopyrrolate, method and apparatus

Publications (2)

Publication Number Publication Date
BR112017003888A2 true BR112017003888A2 (pt) 2018-01-23
BR112017003888B1 BR112017003888B1 (pt) 2022-11-16

Family

ID=51542160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003888-9A BR112017003888B1 (pt) 2014-09-09 2015-09-09 Método de fabricação de uma formulação de pó seco

Country Status (38)

Country Link
US (2) US10532041B2 (pt)
EP (2) EP3191081B1 (pt)
JP (1) JP6502501B2 (pt)
KR (1) KR101927960B1 (pt)
CN (1) CN106604720B (pt)
AP (1) AP2017009777A0 (pt)
AR (1) AR101793A1 (pt)
AU (1) AU2015314272B2 (pt)
BR (1) BR112017003888B1 (pt)
CA (1) CA2960694C (pt)
CL (1) CL2017000560A1 (pt)
CO (1) CO2017003056A2 (pt)
CY (1) CY1124569T1 (pt)
DK (1) DK3191081T3 (pt)
DO (1) DOP2017000065A (pt)
EA (1) EA037332B1 (pt)
EC (1) ECSP17021465A (pt)
ES (1) ES2793905T3 (pt)
HR (1) HRP20201005T1 (pt)
HU (1) HUE049339T2 (pt)
IL (1) IL250427A0 (pt)
LT (1) LT3191081T (pt)
MA (2) MA40617B1 (pt)
MX (1) MX2017003080A (pt)
MY (1) MY181647A (pt)
NZ (1) NZ728435A (pt)
PH (1) PH12017500303A1 (pt)
PL (1) PL3191081T3 (pt)
PT (1) PT3191081T (pt)
RS (1) RS60299B1 (pt)
SG (1) SG11201700536XA (pt)
SI (1) SI3191081T1 (pt)
SV (1) SV2017005403A (pt)
TN (1) TN2017000077A1 (pt)
TW (1) TWI602566B (pt)
UA (1) UA115958C2 (pt)
WO (1) WO2016038116A1 (pt)
ZA (1) ZA201700658B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595631A1 (en) * 2017-03-15 2020-01-22 Vectura Limited Method and formulation
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2004515260A (ja) 2000-04-11 2004-05-27 デュラ・ファーマシューティカルズ・インコーポレイテッド 物理的に安定化された乾燥粉末製剤
WO2002008470A1 (en) 2000-07-20 2002-01-31 Campina B.V. Method for producing a crystalline tableting additive, additive thus obtained and use thereof
CA2429665C (en) 2000-11-30 2013-10-22 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
KR20100095437A (ko) 2007-11-07 2010-08-30 아스트라제네카 아베 아스코르브산 유도체를 포함하는 건조 분말 제제
JP2011506400A (ja) 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
EP2234595B1 (en) 2007-12-13 2012-11-28 Novartis AG Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
EP2417106B1 (en) 2009-04-09 2016-11-30 Novartis AG Process for preparing pyrrolidinium salts
CN102740836A (zh) 2009-04-24 2012-10-17 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
CN102858326A (zh) * 2010-04-01 2013-01-02 奇斯药制品公司 用于制备可吸入干粉所用的载体颗粒的方法
SI2560611T1 (en) 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
RU2018115685A (ru) 2011-02-17 2019-03-05 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
RU2013155903A (ru) 2011-05-17 2015-06-27 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
WO2014007766A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
US20150202297A1 (en) 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
WO2015094927A1 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
UA115958C2 (uk) 2018-01-10
ES2793905T3 (es) 2020-11-17
PL3191081T3 (pl) 2020-09-07
PH12017500303B1 (en) 2017-07-03
PH12017500303A1 (en) 2017-07-03
IL250427A0 (en) 2017-03-30
EP3689332A1 (en) 2020-08-05
RS60299B1 (sr) 2020-07-31
CN106604720B (zh) 2020-03-10
CA2960694C (en) 2021-05-04
DOP2017000065A (es) 2017-07-15
HRP20201005T1 (hr) 2020-10-16
PT3191081T (pt) 2020-05-29
JP6502501B2 (ja) 2019-04-17
MA40617B1 (fr) 2020-05-29
EP3191081A1 (en) 2017-07-19
BR112017003888B1 (pt) 2022-11-16
AR101793A1 (es) 2017-01-11
KR20170054458A (ko) 2017-05-17
TWI602566B (zh) 2017-10-21
MA50680A (fr) 2020-08-05
HUE049339T2 (hu) 2020-09-28
ZA201700658B (en) 2022-05-25
ECSP17021465A (es) 2017-05-31
MY181647A (en) 2020-12-30
TN2017000077A1 (en) 2018-07-04
DK3191081T3 (da) 2020-06-15
MX2017003080A (es) 2017-11-15
AU2015314272B2 (en) 2017-11-23
TW201617072A (zh) 2016-05-16
SI3191081T1 (sl) 2020-07-31
US20200155506A1 (en) 2020-05-21
CL2017000560A1 (es) 2018-03-16
CO2017003056A2 (es) 2017-07-11
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09
US20170258762A1 (en) 2017-09-14
LT3191081T (lt) 2020-07-10
EA201790544A1 (ru) 2017-09-29
EA037332B1 (ru) 2021-03-15
SG11201700536XA (en) 2017-02-27
CA2960694A1 (en) 2016-03-17
NZ728435A (en) 2017-11-24
KR101927960B1 (ko) 2018-12-11
WO2016038116A1 (en) 2016-03-17
CY1124569T1 (el) 2022-03-24
EP3191081B1 (en) 2020-03-25
SV2017005403A (es) 2017-08-23
CN106604720A (zh) 2017-04-26
JP2017527621A (ja) 2017-09-21
US10532041B2 (en) 2020-01-14
MA40617A (fr) 2017-07-19

Similar Documents

Publication Publication Date Title
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
BR112016023422A8 (pt) dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112016000937A2 (pt) formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
GT201400182A (es) Formulaciones farmacéuticas novedosas
ES2969758T3 (es) Composiciones farmacéuticas para usar en la terapia de la blefaritis
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112016025910A2 (pt) uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos
MA40998A (fr) Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
CY1124490T1 (el) Μια διεργασια για την παρασκευη ενος σκευασματος ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
EP3472260A4 (en) COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE OF ACIDIFICATING MATERIALS
BR102015006886B8 (pt) Composição tópicas que compreendem 4-hexilresorcinol e pós e uso
BR112017003888A2 (pt) método de fabricação de uma formulação de pó seco, formulação, inalador de pó seco, uso de partículas comoídas por jatos e cocondicionadas, e, kit farmacêutico.
BR112016026470A2 (pt) Composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
EP3400214A4 (en) COMPOSITIONS OF 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES FOR DRY POWDER INHALATORS
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2015, OBSERVADAS AS CONDICOES LEGAIS